Alteogen is a leading biopharmaceutical company with a robust pipeline of next-generation biologics featuring enhanced efficacy, enabled by its proprietary platform technologies. Founded in 2008, the company is listed on the KOSDAQ stock exchange (KRX:196170). Alteogen’s most distinguished platform, Hybrozyme™, is a novel human hyaluronidase technology that enhances the absorption of biologic drugs administered via subcutaneous injection. This proprietary hyaluronidase demonstrates improved enzymatic activity and thermal stability compared to existing alternatives. Another key innovation, NexP™ fusion technology, is designed to extend the half-life of therapeutic proteins and peptides in the human body. It is currently applied to the development of long-acting biologics, including human growth hormone, exenatide (for diabetes), and Factor VIIa (for hemophilia). The company’s proprietary antibody-drug conjugate platform, NexMab™ ADC technology, enables targeted cancer therapies with improved efficacy and reduced side effects. Using this platform, Alteogen is developing ADC therapeutics for breast, gastric, and ovarian cancers. With extensive expertise and experience, Alteogen has also established its own high-expression cell lines, efficient upstream and downstream processes, and optimized analytical methods to support the development of monoclonal antibody biosimilars.
我們正在追蹤 ALTEOGEN Inc. 的市場擴張
過去 90 日內有 2 個訊號。
ALTEOGEN Inc. 的國際擴張與競爭對手的比較
ALTEOGEN Inc.你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 ALTEOGEN Inc.你 | 0 | 0 | — | 0 | 0 |
目前並無招聘
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
無進行中的廣告活動
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
D&D Pharmatech、Alteogen和Peptron股價急升,因D&D準備在EASL會議上發表MASH管線數據。分析師強調即將公佈的臨床結果和技術轉讓交易。
科斯達克指數因機構拋售下跌2.41%至1084點。阿爾特奧根、佩普特龍和凱爾根等生技股上漲,機器人股在美國半導體下跌後暴跌。
韓國綜合股價指數上漲2.25%至8228.70點,受半導體股推動,SK海力士飆升9.31%,三星電子上漲2.68%,而KOSDAQ下跌3.36%,市場呈現兩極分化。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 ALTEOGEN Inc. 業務、市場及增長訊號的快速解答。
